The Exchange Pulse Report published by Express Scripts predicts that compared with 2014, the year 2015 will see a greater number of younger enrollees signing up on healthcare exchanges, which could potentially drive down drug costs for specialty medications.
The Exchange Pulse Report published by Express Scripts predicts that compared with 2014, the year 2015 will see a greater number of younger enrollees signing up on healthcare exchanges, which could potentially drive down drug costs for specialty medications.
Despite this prediction on drug spending, the report found that specialty drug spending in the exchanges increased by 8% over a year: from 34% in the first quarter (Q1) of last year to 42% during Q1 of the current year. Infectious disease, particularly HIV and Hepatitis C, constituted 21% of the pharmacy spend, with HIV being 53% of the specialty claims. The hepatitis C drugs Harvoni (6.4%) and Sovaldi (3.4%) topped the charts for total pharmacy spend, and were followed by the anti-inflammatory antibody Humira (3.2%).
A particular statistic on the report needs attention: only 5% of health exchange members are responsible for 68% of total pharmacy spend, attributable to their use of high-cost medications. While medication non-adherence was higher on the exchanges compared with health plans, individuals on antidepressants fared worse with medication adherence, while hepatitis C patients did better.
The average age of the exchange enrollee has dropped by nearly 4 years, the report states, from 44.5 in Q1 of 2014, to 40.7 years in Q1 of 2015. Significantly, the number of enrollees with drug claims, and particularly specialty claims, reduced significantly between the 2 quarters being compared. The most expensive conditions treated were diabetes, HIV, and inflammatory conditions in Q1 of 2014; this year, hepatitis C replaced inflammatory conditions.
A point to note: families on exchanges, on average, earn $7260 less than families enrolled with health plans.
Study Highlights BMP7 As a Potential Therapeutic Target for Ovarian Cancer
November 30th 2023High Bone Morphogenetic Protein 7 (BMP7) expression was significantly associated with aggressive phenotypes, including advanced grade, International Federation of Gynecology and Obstetrics stage, residual disease, and adverse overall survival.
Read More
7-Day Dosing of Azacytidine Shows Benefit for Females With High-Risk MDS Not Seen in Males
November 30th 2023Investigators from several medical centers in Japan were surprised to find that women with myelodysplastic syndrome (MDS) had a survival advantage from a 7-day dosing schedule, but that benefit compared with a reduced schedule was not seen in men.
Read More
Oncology Onward: A Conversation With Thyme Care CEO and Cofounder Robin Shah
October 2nd 2023Robin Shah, CEO of Thyme Care, which he founded in 2020 with Bobby Green, MD, president and chief medical officer, joins hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, to discuss his evolution as an entrepreneur in oncology care innovation and his goal of positively changing how patients experience the cancer system.
Listen
Contributor: More Informed Management of Preeclampsia Is Necessary
November 29th 2023At present, it is difficult for clinicians to identify patients at greatest risk for developing preeclampsia with severe features and tailor treatment plans for them; this difficulty increases costs significantly.
Read More
Research Points to Potential MCIDs in Diabetes Distress Scale–17
November 29th 2023Researchers identified a value of at least 0.25 to be a minimal clinically important difference (MCID) in diabetes distress, and MCID values of 0.38 and 0.39 for emotional and interpersonal distress subscales and physician and regimen distress subscales, respectively.
Read More